Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
InFo Hämatologie + Onkologie
Erschienen in: InFo Hämatologie + Onkologie 6/2020

25.06.2020 | Kolorektales Karzinom | Zertifizierte Fortbildung

Kolorektales Karzinom, Mammakarzinom und andere Entitäten

Lebermetastasen - interdisziplinäre Therapie

verfasst von: Dr. med. Marcella Steffani, PD Dr. med. Daniel Hartmann, Prof. Dr. med. Marc Martignoni, Michael W. Müller, Prof. Dr. Alexander Novotny, Prof. Dr. med. Helmut Friess

Erschienen in: InFo Hämatologie + Onkologie | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Auszug

Chirurgie, Systemtherapie, Bestrahlung sowie lokale und vaskuläre Behandlungskonzepte - für die Therapie von Lebermetastasen stehen eine ganze Reihe von unterschiedlichen Ansätzen zur Verfügung. Lesen Sie in der folgenden Übersicht, wann welches Verfahren zum Einsatz kommen sollte, was es jeweils zu beachten gilt und warum eine erfolgreiche Therapie nur in interdisziplinärer Abstimmung gelingen kann. …
Literatur
1.
Abdalla EK et al. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13(10):1271-80
2.
Hoffmann K et al. Liver resection for multimodal treatment of breast cancer metastases: identification of prognostic factors. Ann Surg Oncol. 2010;17(6):1546-54
3.
Frilling A et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15(1):e8-21
4.
Kassahun WT. Controversies in defining prognostic relevant selection criteria that determine long-term effectiveness of liver resection for noncolorectal nonneuroendocrine liver metastasis. Int J Surg. 2015;24(Pt A):85-90
5.
Luedde T et al. Interdisziplinäre Therapie kolorektaler Lebermetastasen. Gastroenterologe. 2016;11(6):479-88
6.
Jara M et al. Reductions in post-hepatectomy liver failure and related mortality after implementation of the LiMAx algorithm in preoperative work-up: a single-centre analysis of 1170 hepatectomies of one or more segments. HPB (Oxford). 2015;17(7):651-8
7.
Ribero D et al. Standardized liver volumetry for portal vein embolization. Semin Intervent Radiol. 2008;25(2):104-9
8.
Angelsen JH et al. Surgery for colorectal liver metastases: the impact of resection margins on recurrence and overall survival. World J Surg Oncol. 2014;12:127
9.
Qadan M, D'Angelica MI. Extending the Limits of Resection for Colorectal Liver Metastases: Positive Resection Margin and Outcome After Resection of Colorectal Cancer Liver Metastases. J Gastrointest Surg. 2017;21(1):196-8
10.
Abdalla EK et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239(6):818-25; discussion 825-7
11.
Adam R et al. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev. 2015;41(9):729-41
12.
van der Poel MJ et al. Multicentre propensity score-matched study of laparoscopic versus open repeat liver resection for colorectal liver metastases. Br J Surg. 2019;106(6):783-9
13.
Martínez-Cecilia D et al. Laparoscopic Versus Open Liver Resection for Colorectal Metastases in Elderly and Octogenarian Patients: A Multicenter Propensity Score Based Analysis of Short- and Long-term Outcomes. Ann Surg. 2017;265(6):1192-1200
14.
Sandström P et al. ALPPS Improves Resectability Compared With Conventional Two-stage Hepatectomy in Patients With Advanced Colorectal Liver Metastasis: Results From a Scandinavian Multicenter Randomized Controlled Trial (LIGRO Trial). Ann Surg. 2018;267(5):833-40
15.
Madoff DC et al. Portal vein embolization in preparation for major hepatic resection: evolution of a new standard of care. J Vasc Interv Radiol. 2005;16(6):779-90
16.
van Lienden KP et al. Portal vein embolization before liver resection: a systematic review. Cardiovasc Intervent Radiol. 2013;36(1):25-34
17.
Abulkhir A et al. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg. 2008;247(1):49-57
18.
Strasberg SM, Phillips C. Use and dissemination of the brisbane 2000 nomenclature of liver anatomy and resections. Ann Surg. 2013;257(3):377-82
19.
Nordlinger B et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208-15
20.
Van Cutsem E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408-17
21.
Folprecht G et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11(1):38-47
22.
Khoo E et al. Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases. HPB (Oxford). 2016;18(6):485-93
23.
Maher B et al. The management of colorectal liver metastases. Clin Radiol. 2017;72(8):617-25
24.
Folprecht G et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005;16(8):1311-9
25.
Ychou M et al. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial. Ann Surg Oncol. 2013;20(13):4289-97
26.
Zorzi D et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg. 2007;94(3):274-86
27.
Ye LC et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol. 2013;31(16):1931-8
28.
Carrato A et al. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). Eur J Cancer. 2017;81:191-202
29.
Geissler M et al. mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO- KRK0109). Ann Oncol. 2018;29(Suppl_5):v108
30.
Schwartzberg LS et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014;32(21):2240-7
31.
Gruenberger T et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol. 2015;26(4):702-8
32.
Rusthoven KE et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27(10):1572-8
33.
Scorsetti M et al. Stereotactic body radiation therapy for liver metastases. J Gastrointest Oncol. 2014;5(3):190-7
34.
Scorsetti M et al. Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up. Radiat Oncol. 2018;13(1):234
35.
Gillams A et al. Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, The Interventional Oncology Sans Frontières meeting 2013. Eur Radiol. 2015;25(12):3438-54
36.
Nosher JL et al. Non-operative therapies for colorectal liver metastases. J Gastrointest Oncol. 2015;6(2):224-40
37.
Rempp H et al. The current role of minimally invasive therapies in the management of liver tumors. Abdom Imaging. 2011;36(6):635-47
38.
Wu YZ et al. Radiofrequency ablation vs hepatic resection for solitary colorectal liver metastasis: a meta-analysis. World J Gastroenterol. 2011;17(36):4143-8
39.
Nielsen K et al. Incidence and treatment of local site recurrences following RFA of colorectal liver metastases. World J Surg. 2013;37(6):1340-7
40.
Solbiati L et al. Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology. 2012;265(3):958-68
41.
Ruers T et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol. 2012;23(10):2619-26
42.
Jiao LR et al. Rapid Induction of Liver Regeneration for Major Hepatectomy (REBIRTH): A Randomized Controlled Trial of Portal Vein Embolisation versus ALPPS Assisted with Radiofrequency. Cancers (Basel). 2019;11(3). pii: E302
43.
Pillai K et al. Heat sink effect on tumor ablation characteristics as observed in monopolar radiofrequency, bipolar radiofrequency, and microwave, using ex vivo calf liver model. Medicine (Baltimore). 2015;94(9):e580
44.
Liang P et al. Malignant liver tumors: treatment with percutaneous microwave ablation--complications among cohort of 1136 patients. Radiology. 2009;251(3):933-40
45.
Pech M et al. MR-guided interstitial laser thermotherapy of colorectal liver metastases: efficiency, safety and patient survival. Eur J Med Res. 2007;12(4):161-8
46.
Vogl TJ et al. Thermal ablation of liver metastases from colorectal cancer: radiofrequency, microwave and laser ablation therapies. Radiol Med. 2014;119(7):451-61
47.
Scheffer HJ et al. Irreversible Electroporation for Colorectal Liver Metastases. Tech Vasc Interv Radiol. 2015;18(3):159-69
48.
Gruber-Rouh T et al. Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: long-term results over a 10-year period. Int J Cancer. 2014;134(5):1225-31
49.
Martin RC 2nd et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer. 2015;121(20):3649-58
50.
Hendlisz A et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010;28(23):3687-94
51.
Wasan HS et al. First-line Selective Internal Radiotherapy Plus Chemotherapy Versus Chemotherapy Alone in Patients With Liver Metastases From Colorectal Cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): A Combined Analysis of Three Multicentre, Randomised, Phase 3 Trials. Lancet Oncol. 2017;18(9):1159-71
Metadaten
Titel
Kolorektales Karzinom, Mammakarzinom und andere Entitäten
Lebermetastasen - interdisziplinäre Therapie
verfasst von
Dr. med. Marcella Steffani
PD Dr. med. Daniel Hartmann
Prof. Dr. med. Marc Martignoni
Michael W. Müller
Prof. Dr. Alexander Novotny
Prof. Dr. med. Helmut Friess
Publikationsdatum
25.06.2020
Verlag
Springer Medizin
Erschienen in
InFo Hämatologie + Onkologie / Ausgabe 6/2020
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762
DOI
https://doi.org/10.1007/s15004-020-8132-2

Weitere Artikel der Ausgabe 6/2020

InFo Hämatologie + Onkologie 6/2020 Zur Ausgabe

Journal club

Apixaban zur Behandlung venöser Thromboembolien bei Krebspatienten

Schwerpunkt

Stellenwert der Thrombozytentransfusion in der Hämatoonkologie

Neues aus der Forschung

Therapieintensivierung kann auch schaden

Info Pharm

Mehr testen, gezielt behandeln

Info Pharm

HCC: Metaanalyse zur Immunkombi

Journal club

Lange Remissionen unter CAR-T-Zell-Therapie

Weitere Lesetipps

Aufklärungsgespräche verbessern – Herausforderungen und Lösungsansätze

Zweitmeinungen – ein Instrument zur Verbesserung der onkologischen Versorgung

Mit neuen Methoden der Gewebediagnostik das Tumormikromilieu ergründen

ANZEIGE

Sichere Antikoagulation bei ständig wechselnden Risikokonstellationen

ANZEIGE

Spagat zwischen Leitlinien und klinischem Alltag

ANZEIGE

Herausforderungen und Management krebsassoziierter Thrombosen

Bildnachweise